Retinoid X receptor agonists enhances type I systemic and intratumoral immunity, but enhanced tumor prevention, with the HER2-IGFBP2-IGF1R plasmid vaccine in two mouse mammary tumor models

Authors

Sasha Stanton, ProvidenceFollow
See full list of authors in comments

Document Type

Abstract

Publication Date

11-1-2023

Keywords

oregon; chiles

Clinical Institute

Cancer

Clinical Institute

Women & Children

Specialty/Research Institute

Oncology

Comments

Stanton SE, Erin R, Drovetti N, Corulli L, Atigadda V, Grubbs C, Sei S, Disis ML. SITC Annual Meeting; November 1-5; San Diego, CA. 2023: 834.